ËÄÉ«AV

Spray drying (SD) and hot-melt extrusion (HME) are commercially proven and accepted amorphous solid dispersion (ASD) technologies for the enhancement of the dissolution and bioavailability of poorly soluble drugs. These approaches are not suitable for all APIs, however. ËÄÉ«AV, in addition to offering non-ASD solutions such as nanomilling and cyclodextrin complexation, is developing an effective coprecipitation technology platform to address this key market need.